A Study of Yervoy and Opdivo Combination Therapy in Participants With Unresectable Advanced/Recurrent Malignant Pleural Mesothelioma (MPM)
The purpose of this study is to observe the safety of the combination therapy with Yervoy and Opdivo in Japanese participants for the treatment of unresectable advanced/recurrent malignant pleural mesothelioma (MPM).
Mesothelioma, Malignant
Incidence of Adverse Events (AEs), Up to 6 Months|Time to onset of serious adverse events (SAEs), Up to 6 Months|Time to onset of AEs, Up to 6 Months|Time to resolution of AEs, Up to 6 Months|Time to resolution of SAEs, Up to 6 Months|Incidence of physician seriousness assessment measured by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Grade - Non-serious AE, Up to 6 Months|Incidence of physician seriousness assessment measured by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Grade - SAE, Up to 6 Months|Incidence of AEs leading to interruption of treatment, Up to 6 Months|Incidence of SAEs leading to interruption of treatment, Up to 6 Months|Incidence of AEs leading to treatment discontinuation, Up to 6 Months|Incidence of SAEs leading to treatment discontinuation, Up to 6 Months|Outcome of reported AEs, Up to 6 Months|Outcome of reported SAEs, Up to 6 Months|Number of participants with Yervoy and Opdivo treatment related adverse events as assessed by physician causality, Up to 6 Months|Number of participants with Yervoy and Opdivo treatment unrelated adverse events as assessed by physician causality, Up to 6 Months
The purpose of this study is to observe the safety of the combination therapy with Yervoy and Opdivo in Japanese participants for the treatment of unresectable advanced/recurrent malignant pleural mesothelioma (MPM).